Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232

Benzinga · 2d ago
Oppenheimer analyst Trevor Allred maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $210 to $232.